Gritstone bio Inc
NASDAQ:GRTS
Intrinsic Value
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. [ Read More ]
The intrinsic value of one GRTS stock under the Base Case scenario is 0.2914 USD. Compared to the current market price of 0.7932 USD, Gritstone bio Inc is Overvalued by 63%.
Valuation Backtest
Gritstone bio Inc
Run backtest to discover the historical profit from buying and selling GRTS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Gritstone bio Inc
Current Assets | 87.4m |
Cash & Short-Term Investments | 79.3m |
Receivables | 231k |
Other Current Assets | 7.9m |
Non-Current Assets | 90.3m |
PP&E | 84.1m |
Other Non-Current Assets | 6.2m |
Current Liabilities | 27.3m |
Accounts Payable | 3.8m |
Accrued Liabilities | 21.2m |
Other Current Liabilities | 2.4m |
Non-Current Liabilities | 98.6m |
Long-Term Debt | 40.1m |
Other Non-Current Liabilities | 58.4m |
Earnings Waterfall
Gritstone bio Inc
Revenue
|
16.3m
USD
|
Operating Expenses
|
-156m
USD
|
Operating Income
|
-139.6m
USD
|
Other Expenses
|
1.1m
USD
|
Net Income
|
-138.5m
USD
|
Free Cash Flow Analysis
Gritstone bio Inc
GRTS Profitability Score
Profitability Due Diligence
Gritstone bio Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Gritstone bio Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
GRTS Solvency Score
Solvency Due Diligence
Gritstone bio Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Gritstone bio Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GRTS Price Targets Summary
Gritstone bio Inc
According to Wall Street analysts, the average 1-year price target for GRTS is 5.6 USD .
Ownership
GRTS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GRTS Price
Gritstone bio Inc
Average Annual Return | 13.55% |
Standard Deviation of Annual Returns | 125.47% |
Max Drawdown | -97% |
Market Capitalization | 153.6m USD |
Shares Outstanding | 193 658 944 |
Percentage of Shares Shorted | 10.49% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 193 full-time employees. The company went IPO on 2018-09-28. The firm discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The firm has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that are collaborating on with Gilead Sciences, Inc. The Company’s product candidates include GRT-C907 (ChAd)/R908 (samRNA), GRT- C909 (ChAd)/R910 (samRNA), GRT-C909 (ChAd)/R910 (samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA).
Contact
IPO
Employees
Officers
The intrinsic value of one GRTS stock under the Base Case scenario is 0.2914 USD.
Compared to the current market price of 0.7932 USD, Gritstone bio Inc is Overvalued by 63%.